India supplies one in every five generic medicines the world needs — and Delhi Chief Minister Rekha Gupta made sure that number echoed across her platform on Tuesday, October 13, 2026, sharing a striking quote from Prime Minister Narendra Modi that frames India's pharmaceutical dominance not just as commerce, but as a civilisational calling.

The quote, attributed to the Prime Minister, reads: 'भारत की प्रगति सबके साथ मिलकर, सबको साथ लेकर आगे बढ़ने की कहानी है।' — 'India's progress is the story of moving forward together, taking everyone along.' Its concrete anchor: when the world reaches for affordable medicine, one in five generic pills traces its origin to an Indian factory.

The 'pharmacy of the world' and how India earned the title

The claim is not mere rhetoric. India's emergence as the global hub for low-cost generics is rooted in decades of deliberate policy — from the 1991 economic liberalisation that opened export corridors, to the 2005 Patents Act amendments that aligned Indian law with international trade norms while fiercely protecting the country's ability to manufacture affordable copies of patented molecules. The result: a pharmaceutical industry that serves patients from sub-Saharan Africa to Southeast Asia at a fraction of what branded drugs would cost.

Successive governments have deepened the sector through manufacturing incentives, export promotion schemes, and health diplomacy with developing nations. The framing — 'taking everyone along' — echoes the Sabka Saath, Sabka Vikas philosophy that has anchored BJP's development messaging, now exported into the language of global public health.

Why Delhi's CM is amplifying a health-diplomacy message

Chief Minister Gupta's decision to share the quote signals alignment between the BJP's state and central leadership on a narrative that is both domestically popular and internationally significant. India's pharma export story resonates with voters who see it as proof that a developing economy can punch far above its weight — not through military or financial power, but through the quiet, life-saving reach of an affordable pill.

The broader pattern is clear: India's political establishment, across administrations, has consistently invested in the 'pharmacy of the world' brand because it simultaneously serves commercial interests, soft-power ambitions, and genuine public health outcomes for billions of people who cannot afford Western drug prices.

The next hard test of that brand will come when pharmaceutical export data for 2026 lands — and when the country's next round of trade negotiations puts medicine pricing back on the table. For now, the message from both New Delhi's national and state leadership is unified: India's progress is inseparable from the world's health.